# TherapeuticsMD, Inc. (TXMD)

- Sector: Healthcare · Industry: Drug Manufacturers Specialty and Generic
- SEC CIK: 0000025743 ([filings on EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000025743))
- Full page: https://inspectstocks.com/stocks/txmd
- Data as of: price 2026-09-25; newest filing used 2026-08-11; latest fiscal period ended 2026-06-30

## Grade

**F-** on the balance-sheet rubric used for lenders, 1 of 5 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | failed | -$217K |  |
| Earnings growing overall | failed | -$217K | $42.7M |
| Earnings growing recently | passed | -$217K | -$569K |
| Earns well on its assets | failed | -0.6% |  |
| Book value per share growing | failed | $2,323.10 | $3,752.19 |

Business quality (the + / − mark): 1 of 6 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | failed | -6.6% |  |
| Healthy profit margin | failed | -6.6% |  |
| Strong operating margin | failed | -120.9% |  |
| Good return on equity | failed | -0.8% |  |
| Debt under control | passed | 0.23 |  |
| Turns sales into cash | failed | -3,163.0% |  |

How the grade works: the letter counts failed checks (none → A, one → B, two → C, three → D, four or more → F). It is built from SEC filings only — the share price never enters it — and describes the business, not whether the stock is worth buying.

## Key figures

In US dollars, as filed.

| Measure | Value |
| --- | --- |
| Revenue, trailing twelve months | $3.3M |
| Net income, trailing twelve months | -$217K |
| Net margin | -6.6% |
| Operating margin | -120.9% |
| Return on equity | -0.8% |
| Debt to equity | 0.23 |
| Diluted EPS, trailing twelve months | -$0.02 |
| Share price | $2.05 |
| Market value | $23.7M |
| Price / sales | 7.3x |

## More on this company

- [Overview](https://inspectstocks.com/stocks/txmd)
- [Financial statements](https://inspectstocks.com/stocks/txmd/financials)
- [Competitors](https://inspectstocks.com/stocks/txmd/peers)
- [Earnings](https://inspectstocks.com/stocks/txmd/earnings)

---

Source: InspectStocks, built from the company’s own SEC filings. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.